Salvato in:
Dettagli Bibliografici
Autori principali: Michio Ozeki, Saori Endo, Shiho Yasue, Ryuta Asada, Akiko M. Saito, Hiroya Hashimoto, Shigeru Ueno, Shoji Watanabe, Motoi Kato, Kyoichi Deie, Shunsuke Nosaka, Mikiko Miyasaka, Akihiro Umezawa, Kentaro Matsuoka, Mototoshi Kato, Tatsuo Kuroda, Takanobu Maekawa, Satoshi Hirakawa, Taizo Furukawa, Shigehisa Fumino, Tatsuro Tajiri, Junkichi Takemoto, Naonori Kawakubo, Akihiro Fujino
Natura: Artículo Open Access
Pubblicazione: Wiley 2025
Soggetti:
Accesso online:https://onlinelibrary.wiley.com/doi/10.1111/ped.70002
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!
_version_ 1867008403691274240
author Michio Ozeki
Saori Endo
Shiho Yasue
Ryuta Asada
Akiko M. Saito
Hiroya Hashimoto
Shigeru Ueno
Shoji Watanabe
Motoi Kato
Kyoichi Deie
Shunsuke Nosaka
Mikiko Miyasaka
Akihiro Umezawa
Kentaro Matsuoka
Mototoshi Kato
Tatsuo Kuroda
Takanobu Maekawa
Satoshi Hirakawa
Taizo Furukawa
Shigehisa Fumino
Tatsuro Tajiri
Junkichi Takemoto
Naonori Kawakubo
Akihiro Fujino
author_facet Michio Ozeki
Saori Endo
Shiho Yasue
Ryuta Asada
Akiko M. Saito
Hiroya Hashimoto
Shigeru Ueno
Shoji Watanabe
Motoi Kato
Kyoichi Deie
Shunsuke Nosaka
Mikiko Miyasaka
Akihiro Umezawa
Kentaro Matsuoka
Mototoshi Kato
Tatsuo Kuroda
Takanobu Maekawa
Satoshi Hirakawa
Taizo Furukawa
Shigehisa Fumino
Tatsuro Tajiri
Junkichi Takemoto
Naonori Kawakubo
Akihiro Fujino
Michio Ozeki
Saori Endo
Shiho Yasue
Ryuta Asada
Akiko M. Saito
Hiroya Hashimoto
Shigeru Ueno
Shoji Watanabe
Motoi Kato
Kyoichi Deie
Shunsuke Nosaka
Mikiko Miyasaka
Akihiro Umezawa
Kentaro Matsuoka
Mototoshi Kato
Tatsuo Kuroda
Takanobu Maekawa
Satoshi Hirakawa
Taizo Furukawa
Shigehisa Fumino
Tatsuro Tajiri
Junkichi Takemoto
Naonori Kawakubo
Akihiro Fujino
collection Wiley Open Access
contents Sirolimus treatment for intractable vascular anomalies ( SIVA ): An open‐label, single‐arm, multicenter, prospective trial Michio Ozeki Saori Endo Shiho Yasue Ryuta Asada Akiko M. Saito Hiroya Hashimoto Shigeru Ueno Shoji Watanabe Motoi Kato Kyoichi Deie Shunsuke Nosaka Mikiko Miyasaka Akihiro Umezawa Kentaro Matsuoka Mototoshi Kato Tatsuo Kuroda Takanobu Maekawa Satoshi Hirakawa Taizo Furukawa Shigehisa Fumino Tatsuro Tajiri Junkichi Takemoto Naonori Kawakubo Akihiro Fujino Pediatrics International Abstract Background Intractable vascular anomalies (VAs), including vascular tumors and venous, lymphatic, and mixed malformations, often have severe symptoms and a poor prognosis, highlighting the need for new treatments. We conducted a prospective trial of sirolimus (tablet and granule forms) for the treatment of VAs. Methods In this open‐label, single‐arm, multicenter trial across four Japanese institutions, patients with VAs received oral sirolimus daily, targeting a trough concentration of 5–15 ng/mL. We evaluated response rates (radiological volume changes in lesions), skin lesions, performance status, respiratory function, visceral symptoms (bleeding, pain), laboratory data, quality of life, and safety at 12, 24, and 52 weeks. Results Thirteen patients with VAs were treated with sirolimus. Seven patients (53.8%; 95% confidence interval: 25.1%–80.8%) showed a partial radiological response at 24 weeks, with no complete responses, and 61.5% had a partial response by 12 weeks, with little subsequent change in patients who had stable disease thereafter. Improvements in skin lesions, blood coagulation, and activities of daily living were noted. Common adverse events included stomatitis, dermatitis, diarrhea, and fever. Conclusions Sirolimus may reduce VA tissue volume and potentially improve symptoms and activities of daily living in patients with VAs. 10.1111/ped.70002 http://creativecommons.org/licenses/by/4.0/
doi_str_mv 10.1111/ped.70002
format Artículo Open Access
id wiley_oa_10_1111_ped_70002
institution Wiley Open Access
license_str_mv http://creativecommons.org/licenses/by/4.0/
publishDate 2025
publisher Wiley
record_format wiley_oa
spellingShingle Sirolimus treatment for intractable vascular anomalies ( SIVA ): An open‐label, single‐arm, multicenter, prospective trial
Michio Ozeki
Saori Endo
Shiho Yasue
Ryuta Asada
Akiko M. Saito
Hiroya Hashimoto
Shigeru Ueno
Shoji Watanabe
Motoi Kato
Kyoichi Deie
Shunsuke Nosaka
Mikiko Miyasaka
Akihiro Umezawa
Kentaro Matsuoka
Mototoshi Kato
Tatsuo Kuroda
Takanobu Maekawa
Satoshi Hirakawa
Taizo Furukawa
Shigehisa Fumino
Tatsuro Tajiri
Junkichi Takemoto
Naonori Kawakubo
Akihiro Fujino
Pediatrics International
Sirolimus treatment for intractable vascular anomalies ( SIVA ): An open‐label, single‐arm, multicenter, prospective trial Michio Ozeki Saori Endo Shiho Yasue Ryuta Asada Akiko M. Saito Hiroya Hashimoto Shigeru Ueno Shoji Watanabe Motoi Kato Kyoichi Deie Shunsuke Nosaka Mikiko Miyasaka Akihiro Umezawa Kentaro Matsuoka Mototoshi Kato Tatsuo Kuroda Takanobu Maekawa Satoshi Hirakawa Taizo Furukawa Shigehisa Fumino Tatsuro Tajiri Junkichi Takemoto Naonori Kawakubo Akihiro Fujino Pediatrics International Abstract Background Intractable vascular anomalies (VAs), including vascular tumors and venous, lymphatic, and mixed malformations, often have severe symptoms and a poor prognosis, highlighting the need for new treatments. We conducted a prospective trial of sirolimus (tablet and granule forms) for the treatment of VAs. Methods In this open‐label, single‐arm, multicenter trial across four Japanese institutions, patients with VAs received oral sirolimus daily, targeting a trough concentration of 5–15 ng/mL. We evaluated response rates (radiological volume changes in lesions), skin lesions, performance status, respiratory function, visceral symptoms (bleeding, pain), laboratory data, quality of life, and safety at 12, 24, and 52 weeks. Results Thirteen patients with VAs were treated with sirolimus. Seven patients (53.8%; 95% confidence interval: 25.1%–80.8%) showed a partial radiological response at 24 weeks, with no complete responses, and 61.5% had a partial response by 12 weeks, with little subsequent change in patients who had stable disease thereafter. Improvements in skin lesions, blood coagulation, and activities of daily living were noted. Common adverse events included stomatitis, dermatitis, diarrhea, and fever. Conclusions Sirolimus may reduce VA tissue volume and potentially improve symptoms and activities of daily living in patients with VAs. 10.1111/ped.70002 http://creativecommons.org/licenses/by/4.0/
title Sirolimus treatment for intractable vascular anomalies ( SIVA ): An open‐label, single‐arm, multicenter, prospective trial
topic Pediatrics International
url https://onlinelibrary.wiley.com/doi/10.1111/ped.70002